5-HT6 Receptor Antagonist for Dementia-Related Cognitive Decline
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective treatments for dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment, and behavioral changes such as agitation or aggression, as current therapies like hormone replacement therapy and cholinesterase inhibitors have negative side effects, and no approved interventions exist for these conditions.
Innovation Solution
The use of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or its pharmaceutically acceptable salts, to treat these conditions by administering a therapeutically effective amount to patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy is used to treat cognitive decline in post-menopausal women, then cognitive function may be improved, but the risk of serious side effects increases including uterine, ovarian and breast cancers, pulmonary embolism, cardiac disease and stroke
Solution Approach 1:
The patent extracts and isolates the beneficial cognitive effects from hormone replacement therapy by identifying a specific non-hormonal mechanism (5-HT6 receptor antagonism) that can achieve memory improvement without the harmful hormonal side effects. This separates the desired therapeutic outcome from the harmful associations.
Solution Approach 2:
The patent introduces a new intermediary mechanism (5-HT6 receptor antagonism) that mediates cognitive improvement through a different pathway than hormone replacement therapy. This intermediary approach achieves the same therapeutic goal (cognitive function improvement) through an alternative mechanism that avoids the harmful side effects of hormonal intervention.
2Reliability
If cholinesterase inhibitors are used to treat menopause related memory and cognitive loss, then acetylcholine levels increase, but the treatment is no more effective than placebo
Solution Approach 1:
The patent changes the therapeutic parameter from increasing acetylcholine levels (cholinesterase inhibition) to blocking 5-HT6 receptors. This parameter change represents a shift to a different neurotransmitter system and mechanism of action, moving beyond the saturated and ineffective cholinesterase inhibitor approach to achieve cognitive improvement.
3Adaptability or versatility
If no alternative therapy is approved for post-menopausal dementia, then unmet medical need remains, but this creates an opportunity for new treatment approaches
Solution Approach 1:
The patent segments the dementia treatment market by identifying and addressing the specific unmet need in post-menopausal women, a distinct population with unique hormonal and cognitive characteristics. This segmentation allows for targeted development of 5-HT6 receptor antagonists specifically for this population, improving quality of life where no approved therapies exist.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 5-HT6 receptor antagonist significantly improves memory deficits and reduces aggression levels in animal models of menopause-related cognitive decline, senile dementia, vascular dementia, and chemotherapy-induced cognitive impairment, as well as behavioral changes associated with dementia.
Implementation Method 1
Serotonin-6 (5-HT6) receptor antagonist also works by increasing the brain acetylcholine levels
Data Source
AI summary
The present invention relates to new uses of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment and behavioral changes in dementia such as agitation, aggression, depression, anxiety, psychosis, disinhibition, or sleep disturbances. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.